Vol 34,2025 No.7 | Articles | Chinese Journal of Pharmacoepidemiology

Home Articles Vol 34,2025 No.7

 Contents

Vol 34,2025 No.7

Date of publication: July 15, 2025

 Get cover  Get contents

 Prev
Vol 34,2025 No.6

Guide on Methodological Standards in Pharmacoepidemiology in China (2nd edition) and their series interpretation (7): selection of control groups

TIAN Qinxi ZHAN Siyan SUN Feng YANG Zhirong

2025,34(7):725-733

Pharmacoepidemiology Methodology Guidelines Control Interventional research Non-interventional research
Details Download Mobile

Evaluation of the efficacy and safety of dapagliflozin and empagliflozin in the treatment of patients with diabetic nephropathy based on real-world data

HU Ruiwen JI Cheng LI Li

2025,34(7):734-742

Diabetic nephropathy Dapagliflozin Empagliflozin Real world study Efficacy Safety
Details Download Mobile
Development and application of a rapid identification algorithm for cutaneous lupus erythematosus and its subtypes based on medical insurance databases

WANG Yutong MENG Xianglong PAN Yu WEI Chen JIN Hui WANG Shengfeng

2025,34(7):743-752

Cutaneous lupus erythematosus Medical insurance Rapid identification algorithm
Details Download Mobile
Efficacy of oxycodone combined with midazolam as medication for ERCP under awake sedation

LI Yingying FENG Chenxi FENG Anqiang

2025,34(7):753-761

Oxycodone Midazolam Endoscopic retrograde cholangiopancreatography Awake sedation
Details Download Mobile
Clinical study of lamotrigine combined with magnesium valproate in children with depressive episodes of bipolar disorder

LIANG Hai ZHAO Feng CHEN Huijuan JIANG Mengyu DI Panpan YANG Miao

2025,34(7):762-770

Lamotrigine Magnesium valproate Bipolar disorder Depression Children Thyroid hormone Inflammatory factor Brain-derived neurotrophic factor
Details Download Mobile
Safety of budesonide inhalation aerosol for chronic obstructive pulmonary disease: a Meta-analysis

QIN Honghua GUO Haiyan LI Haifeng TONG Xiaona WANG Ying

2025,34(7):771-784

Budesonide Chronic obstructive pulmonary disease Adverse drug reaction Meta-analysis Randomized controlled trial
Details Download Mobile
Efficacy and safety of tislelizumab combined with anlotinib in the treatment of advanced non-small cell lung cancer: a Meta-analysis

TENG Xinli LIU Bin XIU Junli ZHOU Xiaohong

2025,34(7):785-794

Tislelizumab Anlotinib Non-small cell lung cancer Meta-analysis Systematic review
Details Download Mobile
Efficacy and safety of dose-optimization strategies for CDK4/6 inhibitors in HR+/HER2- advanced breast cancer: a Meta-analysis

ZHENG Yating LIU Songling ZHOU Liyan

2025,34(7):795-805

CDK4/6 inhibitor HR+/HER2- breast cancer Dose-optimization Meta-analysis
Details Download Mobile
Sugemalimab as first-line treatment for non-small cell lung cancer: a rapid health technology assessment

HOU Yibing KANG Shuo GONG Yuan WANG Xiaohui NIE Ying LIU Huanlong

2025,34(7):806-814

Sugemalimab Non-small cell lung cancer Effectiveness Safety Economics Rapid health technology assessment
Details Download Mobile
Bibliometric analysis of researches on glucocorticoids use in systemic lupus erythematosus from 2004 to 2024

BAI Jie DONG Liming SONG Zhihui WANG Jiawei

2025,34(7):815-823

Glucocorticoids Systemic lupus erythematosus Bibliometric Research hotspot
Details Download Mobile